Cross-sectional monitoring of Wilms' tumor gene 1 (WT1) expression in Iranian patients with acute lymphoblastic leukemia at diagnosis, relapse and remission

References

• Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38: 139–152
   PubMedGoogle Scholar
• Moppett J, Burke G A, Steward C G, Oakhill A, Goulden N J. The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. J Clin Pathol 2003; 56: 249–253
   PubMed Web of Science ®Google Scholar
• Toubai T, Tanaka J, Ota S, Fukuhara T, Hashino S, Kondo T, et al. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients. Am J Hematol 2005; 80: 181–187
   PubMed Web of Science ®Google Scholar
• Taube T, Eckert C, Korner G, Henze G, Seeger K. Real-time quantification of TEL-AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic leukaemia. Comparison with antigen receptor-based MRD quantification methods. Leuk Res 2004; 28: 699–706
   PubMed Web of Science ®Google Scholar
• Te Kronnie G, Bicciato S, Franceschini L, Accordi B, Delliorto M C, Rinaldi A, et al. Validation by RQ-PCR and flow cytometry of alpha-defensin1 – 3 (DEFA1-3) overexpression in relapsed and refractory acute lymphoblastic leukemia. Oncol Rep 2006; 15: 341–346
   PubMed Web of Science ®Google Scholar
• Coppes M J, Campbell C E, Williams B R. The role of WT1 in Wilms tumorigenesis. Faseb J 1993; 7: 886–895
   PubMed Web of Science ®Google Scholar
• Kletzel M, Olzewski M, Huang W, Chou P M. Utility of WT1 as a reliable tool for the detection of minimal residual disease in children with leukemia. Pediatr Dev Pathol 2002; 5: 269–275
   PubMed Web of Science ®Google Scholar
• Wagner K D, Wagner N, Schedl A. The complex life of WT1. J Cell Sci 2003; 116: 1653–1658
   PubMed Web of Science ®Google Scholar
• Cilloni D, Gottardi E, Saglio G. WT1 overexpression in acute myeloid leukemia and myelodysplastic syndromes. Methods Mol Med 2006; 125: 199–211
   PubMedGoogle Scholar
• Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071–3079
   PubMed Web of Science ®Google Scholar
• Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006; 19: 804–814
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885–13890
   PubMed Web of Science ®Google Scholar
• Siehl J M, Reinwald M, Heufelder K, Menssen H D, Keilholz U, Thiel E. Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants. Ann Hematol 2004; 83: 745–750
   PubMed Web of Science ®Google Scholar
• Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O, et al. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 2006; 20: 254–263
   PubMed Web of Science ®Google Scholar
• Spanaki A, Linardakis E, Perdikogianni C, Stiakaki E, Morotti A, Cilloni D, et al. Quantitative assessment of WT1 expression in diagnosis of childhood acute leukemia. Leuk Res 2007; 31: 570–572
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Kawakami M, Elisseeva O A, Nakajima H, Udaka K, et al. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem 2006; 13: 2345–2352
   PubMed Web of Science ®Google Scholar
• Sugiyama H. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. Expert Rev Vaccines 2005; 4: 503–512
   PubMed Web of Science ®Google Scholar
• Vidriales M B, Perez J J, Lopez-Berges M C, Gutierrez N, Ciudad J, Lucio P, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003; 101: 4695–4700
   PubMed Web of Science ®Google Scholar
• Henze G, Langermann H J, Ritter J, Schellong G, Riehm H. Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: a report from the BFM Study Group. Haematol Blood Transfus 1981; 26: 87–93
   PubMedGoogle Scholar
• Ludwig W D, Reiter A, Loffler H, Gokbuget, Hoelzer D, Riehm H, et al. Immunophenotypic features of childhood and adult acute lymphoblastic leukemia (ALL): experience of the German Multicentre Trials ALL-BFM and GMALL. Leuk Lymphoma 1994; 13(Suppl 1)71–76
   PubMed Web of Science ®Google Scholar
• Gharagozlou S, Ghods R, Bahrami Z S, Roohi A, Jeddi-Tehrani M, Conti-Fine B M, et al. Characterization of human hybridoma clones isolated from hemophilia patients with specificity for different domains of coagulating factor VIII. Hum Antibodies 2003; 12: 67–76
   PubMedGoogle Scholar
• Asgarian Omran H, Shabani M, Shahrestani T, Sarafnejad A, Khoshnoodi J, Vossough P, et al. Immunophenotypic subtyping of leukemic cells from Iranian patients with acute lymphoblastic leukaemia: association to disease outcome. Iran J Immunol 2007; 4: 15–25
   PubMedGoogle Scholar
• Shibuya H, Nagai T, Ishii A, Yamamoto K, Hirohata S. Differential regulation of Th1 responses and CD154 expression in human CD4+ T cells by IFN-alpha. Clin Exp Immunol 2003; 132: 216–224
   PubMed Web of Science ®Google Scholar
• Baird P N, Simmons P J. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997; 25: 312–320
   PubMed Web of Science ®Google Scholar
• Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H, et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 2002; 116: 409–420
   PubMed Web of Science ®Google Scholar
• Olszewski M, Huang W, Chou P M, Duerst R, Kletzel M. Wilms' tumor 1 (WT1) gene in hematopoiesis: a surrogate marker of cell proliferation as a possible mechanism of action?. Cytotherapy 2005; 7: 57–61
   PubMed Web of Science ®Google Scholar
• Chen J S, Hsiao C C, Sheen J M, Cheng C N. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia. Leuk Res 2007; 31: 1351–1357
   PubMed Web of Science ®Google Scholar
• Gaiger A, Linnerth B, Mann G, Schmid D, Heinze G, Tisljar K, et al. Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol. Eur J Haematol 1999; 63: 86–93
   PubMed Web of Science ®Google Scholar
• Im H J, Kong G, Lee H. Expression of Wilms tumor gene (WT1) in children with acute leukemia. Pediatr Hematol Oncol 1999; 16: 109–118
   PubMed Web of Science ®Google Scholar
• Jian Z, Chen F, Xie Q, Liu W, Zhong M. Expression of WT1 gene mRNA in leukemia. Hunan Yi Ke Da Xue Xue Bao 1999; 24: 341–342
   PubMedGoogle Scholar
• Magyarosy E, Varga N, Timar J, Raso E. Follow-up of minimal residual disease in acute childhood lymphoblastic leukemia by WT1 gene expression in the peripheral blood: the Hungarian experience. Pediatr Hematol Oncol 2003; 20: 65–74
   PubMed Web of Science ®Google Scholar
• Menssen H D, Renkl H J, Rodeck U, Maurer J, Notter M, Schwartz S, et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9: 1060–1067
   PubMed Web of Science ®Google Scholar
• Miwa H, Beran M, Saunders G F. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405–409
   PubMed Web of Science ®Google Scholar
• Patmasiriwat P, Fraizer G, Kantarjian H, Saunders G F. WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia 1999; 13: 891–900
   PubMed Web of Science ®Google Scholar
• Wu X, Wang Y, Pei X. Expression of Wilms' tumor gene (WT1) in leukemias and its clinical implication. Zhonghua Xue Ye Xue Za Zhi 1998; 19: 16–19
   PubMedGoogle Scholar
• Gaiger A, Schmid D, Heinze G, Linnerth B, Greinix H, Kalhs P, et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 1998; 12: 1886–1894
   PubMed Web of Science ®Google Scholar
• Forestier E, Johansson B, Borgstrom G, Kerndrup G, Johansson J, Heim S. Cytogenetic findings in a population-based series of 787 childhood acute lymphoblastic leukemias from the Nordic countries. The NOPHO Leukemia Cytogenetic Study Group. Eur J Haematol 2000; 64: 194–200
   PubMed Web of Science ®Google Scholar
• Sazawal S, Bhatia K, Gurbuxani S, Singh Arya L, Raina V, et al. Pattern of immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements in childhood acute lymphoblastic leukemia in India. Leuk Res 2000; 24: 575–582
   PubMed Web of Science ®Google Scholar
• Asgarian H, Shabani M, Vossough P, Sharifian R, Gharagozlou S, Khoshnoodi J, et al. Over-expression of Wilm's Tumor Gene 1 (WT1) in Iranian patients with acute myeloblastic leukemia. Iran J Immunol 2005; 2: 182–190
   Google Scholar
• Niegemann E, Wehner S, Kornhuber B, Schwabe D, Ebener U. wt1 gene expression in childhood leukemias. Acta Haematol 1999; 102: 72–76
   PubMed Web of Science ®Google Scholar
• Ozgen U, Anak S, Ozbek U, Sarper N, Eryilmaz E, Agaoglu L, et al. wt1 gene expression in childhood acute leukemias. Acta Haematol 2000; 103: 229–330
   PubMed Web of Science ®Google Scholar
• Tamaki H, Ogawa H, Inoue K, Soma T, Yamagami T, Miyake S, et al. Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia. Blood 1996; 88: 4396–4398
   PubMed Web of Science ®Google Scholar
• Ramirez O, Linares A, Trujillo M L, Caminos J E. WT1 mRNA in cerebrospinal fluid associated with relapse in pediatric lymphoblastic leukemia. J Pediatr Hematol Oncol 2003; 25: 453–458
   PubMed Web of Science ®Google Scholar
• Menssen H D, Renkl H J, Rodeck U, Kari C, Schwartz S, Thiel E. Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia. Int J Cancer 1997; 70: 518–523
   PubMed Web of Science ®Google Scholar
• Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi Y C, Ohtsuki Y, et al. WT1 (Wilms' Tumor 1) Peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 2007; 51: 519–530
   PubMed Web of Science ®Google Scholar
• Kawakami M, Oka Y, Tsuboi A, Harada Y, Elisseeva O A, Furukawa Y, et al. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 mug/body) in a patient with chronic myelomonocytic leukemia. Int J Hematol 2007; 85: 426–429
   PubMed Web of Science ®Google Scholar